Close Menu
Home › Natera, BGI Genomics Ink $50M Deal to Develop, Launch Liquid Biopsy Tests in China, Elsewhere

Natera, BGI Genomics Ink $50M Deal to Develop, Launch Liquid Biopsy Tests in China, Elsewhere

Mar 11, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Natera and BGI Genomics said today that they have signed a $50 million partnership to commercialize Natera's circulating tumor DNA Signatera minimal residual disease (MRD) test in China and to develop reproductive health tests in "select markets," all using BGI's sequencing technology and instruments.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
30
Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31
Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

What's Popular?

In Sequencing

  1. Cowen, William Blair, JP Morgan Initiate Coverage of Adaptive Biotechnologies

  2. Interpace Diagnostics, SelectHealth Sign Coverage Agreement for Thyroid Cancer Tests

  3. Parkinson's Foundation, Fulgent Genetics Partner on Genetic Testing Initiative

  4. Parkinson's Foundation Project Seeks to ID Patient Disease Variants to Guide Therapy

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.